Return to Publications
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Return to Publications  |  Return to CINJ Home
Rutgers Cancer Institute of New Jersey's Cancer Connection, April 2014
Donate NowThe latest news on research, treatment, prevention and education from the
state's only National Cancer Institute-designated Comprehensive Cancer Center
$4.25M Award Supports Development of Innovative Clinical Trials



The movement to 'personalize' cancer treatments continues to grow, with researchers making advances in identifying targeted therapies and understanding what drives them. Physician scientists at Rutgers Cancer Institute of New Jersey are aiming to build on that momentum with the development of innovative early-phase clinical trials examining genomic and therapeutic biomarkers. Supporting this effort is a $4.25 million grant (UM1CA186716) from the National Cancer Institute. The initiative led by Cancer Institute of New Jersey Director Robert S. DiPaola, MD, includes the University of Wisconsin Carbone Cancer Center and aims to provide patients in New Jersey and nationwide with access to new targeted therapies through clinical trials.Learn more

Surgeon Performs First-in-Region Single-Incision Robotic Hysterectomy



Mira Hellmann, MD, a gynecologic oncologist at Rutgers Cancer Institute of New Jersey is the first in the central New Jersey region to have performed a single-incision hysterectomy using a robotic method at Robert Wood Johnson University Hospital. The 'single port' method strategically places the incision near the belly-button to achieve a somewhat 'scarless' surgery. Hellmann is also an assistant professor of obstetrics, gynecology and reproductive sciences at Rutgers Robert Wood Johnson Medical School.Learn more

Rutgers Cancer Institute of New Jersey Pediatric Leader Named as Vice Chair of National Panel



Richard Drachtman, MD, interim chief of pediatric hematology/ oncology at Rutgers Cancer Institute of New Jersey has been appointed as Vice Chair of the National Cancer Institute Pediatric Central Institutional Review Board (PedCIRB). The PedCIRB reviews NCI-sponsored pediatric clinical trials conducted by the world's largest pediatric cancer research entity known as the Children's Oncology Group. Drachtman, a professor of pediatrics at Rutgers Robert Wood Johnson Medical School, is widely recognized for his clinical expertise and research in childhood cancer and sickle cell disease and has served as a panel member since 2009.Learn more

Bike Ride Marks a Decade of Supporting Cancer Research


Century for the Cure

Marking a decade of supporting research at Rutgers Cancer Institute of New Jersey, the Century for the Cure charity bike ride is gearing up for another successful year. This year's ride will add to the $1.2 million already raised to support innovative early-stage clinical trials in leukemia, lymphomas and kidney cancer. Registration is now open for the September 14 event.Learn more

            Rutgers Cancer Institute of New Jersey                                          NCI logo 

Office of Communications         ·        ·        732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List